Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 53

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2018

Summary

According to the recently published report 'Nociceptin Receptor - Pipeline Review, H2 2018'; Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid receptor is a protein encoded by the OPRL1 (opioid receptor-like 1) gene. NOP receptors are located both pre- and post-synaptically in various areas of CNS. The nociceptin receptor (NOP) and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.

The report 'Nociceptin Receptor - Pipeline Review, H2 2018' outlays comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 6 and 1 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones and Immunology which include indications Pain, Substance (Drug) Abuse, Neuropathic Pain (Neuralgia), Dyskinesia, Nociceptive Pain, Bladder Pain, Cancer Pain, Diabetic Neuropathic Pain, Drug Addiction, Hypersensitivity, Inflammatory Pain, Low Back Pain, Major Depressive Disorder, Osteoarthritis Pain, Overactive Bladder, Parkinson's Disease and Post-Traumatic Stress Disorder (PTSD).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)

- The report reviews Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Overview
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Companies Involved in Therapeutics Development
Blackthorn Therapeutics Inc
Grunenthal GmbH
Recordati SpA
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Drug Profiles
AT-076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTRX-246040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cebranopadol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRT-6010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OREX-1038 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Agonize ORL1 for Acute Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-0438 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Dormant Products
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Discontinued Products
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Product Development Milestones
Featured News & Press Releases
Aug 29, 2018: Scientists take big step toward finding non-addictive pain killer
Dec 07, 2017: BlackThorn Therapeutics Presents Preclinical and Clinical Data from Its First-in-Class NOPR Antagonist at American College of Neuropsychopharmacology Annual Meeting
Jul 24, 2017: BlackThorn Therapeutics Enrolls First Patient in Phase 2a Study of Lead Compound, BTRX-246040, in Major Depressive Disorder
Jul 10, 2017: Orexigen Announces Presentation of Preclinical Data for OREX-1038 at the International Narcotics Research Conference
Jan 05, 2017: Orexigen Therapeutics Provides Update on OREX-1038 at 35th Annual J.P. Morgan Healthcare Conference
Sep 30, 2016: Grunenthal's cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain
Aug 09, 2016: NIH Grant Will Fund Development of Small Molecules for Post-Traumatic Stress Disorder
May 23, 2016: Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory Profile
Feb 29, 2016: Cebranopadol Top-Line Data from Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Blackthorn Therapeutics Inc, H2 2018
Pipeline by Grunenthal GmbH, H2 2018
Pipeline by Recordati SpA, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 - 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts
    Published: 18-Feb-2019        Price: US 1290 Onwards        Pages: 105
    The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscape, and discusses major trends. The report offers the most up-to-date industry ......
  • Global Vegetable (HPMC) Capsule Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Feb-2019        Price: US 3480 Onwards        Pages: 124
    HPMC Capsules are two-piece capsules made from cellulosic raw materials that satisfy vegetarian, religion, cultural and policy needs. These vegetable capsules are an attractive, all natural dosage form that retain all the advantages - easy to swallow, effectively mask taste and odor, and allow product visibility. These capsules are also starch-free, gluten-free and preservative-free, and meet the strict dietary needs of customers that choose a vegetarian lifestyle. HPMC (Hydroxypropyl methylcell......
  • Global Enteric Empty Capsules Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Feb-2019        Price: US 3480 Onwards        Pages: 119
    Enteric Empty Capsules is a niche type of empty capsules that can prevent the material inside destroyed in gastric area. Scope of the Report: This report includes the estimation of market size for value (million USD) and volume (M Capsules). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Enteric Empty Capsules market, to estimate the size of various other dependent submarkets in the overall market. Key players in the marke......
  • Global Hepatocyte Growth Factor Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Feb-2019        Price: US 3480 Onwards        Pages: 121
    Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing. Scope of the Report: The application......
  • Global VOG (Video-oculography) Apparatus Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Feb-2019        Price: US 3480 Onwards        Pages: 117
    Video-oculography (VOG) is a non-invasive, video-based method of measuring horizontal, vertical and torsional position components of the movements of both eyes (eye tracking) using a head-mounted mask that is equipped with small cameras. VOG is usually employed for medical purposes. This report studies the VOG (Video-oculography) Apparatus market, and the equipment used for research are not included in our report. Scope of the Report: In the last several yea......
  • Global Liquid Chromatography Detectors Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Feb-2019        Price: US 3480 Onwards        Pages: 124
    Liquid Chromatography Detectors is a device used in liquid chromatography (LC) to detect components of the mixture being eluted off the chromatography column. A broad range of detectors is available to meet different sample requirements. Specific detectors respond to a particular compound only and the response is independent of mobile phase composition. On the other hand the response of bulk property detectors is dependent on collective changes in composition of sample and mobile phase. ......
  • Global Otoscope Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Feb-2019        Price: US 3480 Onwards        Pages: 136
    This report studies the Otoscope market. Otoscope is a medical device which is used to look into the ears. Health care providers use otoscopes to screen for illness during regular check-ups and also to investigate ear symptoms. An otoscope potentially gives a view of the ear canal and tympanic membrane or eardrum. Scope of the Report: In the last several years, the United States market of Otoscope developed smoothly, with an average growth rate of 3.8 %. In 2017, United Sta......
  • Global Spine Surgery Products Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Feb-2019        Price: US 3480 Onwards        Pages: 135
    The report is about Spine Surgery Products market. Spinal fusion products are used in spinal fusion surgery. The products are involved in removing the damaged disc and replacing it with any fusion products. Non-fusion products are used during spine surgery, which are implanted to treat spine conditions. This also allows the patient to retain its movement and flexibility. The non-fusion products are becoming the treatment of choice, especially for the younger, more active patient. Increase in num......
  • Global Vinpocetine Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Feb-2019        Price: US 3480 Onwards        Pages: 120
    Vinpocetine is a synthetic derivative of the vinca alkaloid vincamine, an extract from the lesser periwinkle plant. Vinpocetine was first isolated from the plant in 1975 by the Hungarian chemist Csaba Szántay. The mass production of the synthetic compound was started in 1978 by the Hungarian pharmaceutical company Richter Gedeon. The indications is improvement all symptoms of cerebral infarction and cerebral hemorrhage sequela, cerebrovascular atherosclerosis Scope of the Report:......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs